Alumis
Pauline Henry is a highly experienced professional in Quality Assurance and Quality Systems, currently serving as Director of Quality Systems at Alumis since February 2023. Pauline previously held the position of Associate Director of Quality Assurance at Ambys Medicines, where responsibilities included establishing the QA function, implementing a Quality Management System (QMS) compliant with cGMP requirements, and leading the commissioning of a cGMP facility. Prior roles include Senior Quality Assurance Manager at Orchard Therapeutics, where enhancements were made to QMS for gene therapies, and positions at VIVUS, Inc. and IncellDx, focusing on compliance and improvement of quality systems. Earlier experience includes a significant role at Arbor Vita Corporation, contributing to the development of a diagnostic test for cervical cancer. Pauline holds a Master's degree in Biotechnology Engineering and has completed certification as a Lead Auditor for ISO 13485.
This person is not in any teams
This person is not in any offices
Alumis
2 followers
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.